Login / Signup

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.

Jing GaoZhengyi WangWenqing JiangYanni ZhangZhen MengYanling NiuZhen ShengChan ChenXuejun LiuXi ChenChanjuan LiuKeren JiaCheng ZhangHaiyan LiaoJaeho JungEunsil SungHyejin ChungJingwu Z ZhangAndrew X ZhuLin Shen
Published in: Journal for immunotherapy of cancer (2023)
T cells in tumor microenvironment to avoid the risk of liver toxicity and systemic immune response.
Keyphrases
  • immune response
  • growth factor
  • oxidative stress
  • toll like receptor
  • recombinant human
  • inflammatory response